452 related articles for article (PubMed ID: 23816060)
1. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].
Bouron A; Lorrain E
Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060
[TBL] [Abstract][Full Text] [Related]
2. The antidepressant hyperforin increases the phosphorylation of CREB and the expression of TrkB in a tissue-specific manner.
Gibon J; Deloulme JC; Chevallier T; Ladevèze E; Abrous DN; Bouron A
Int J Neuropsychopharmacol; 2013 Feb; 16(1):189-98. PubMed ID: 22226089
[TBL] [Abstract][Full Text] [Related]
3. The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria.
Tu P; Gibon J; Bouron A
J Neurochem; 2010 Jan; 112(1):204-13. PubMed ID: 19845832
[TBL] [Abstract][Full Text] [Related]
4. Cellular neurobiology of hyperforin.
Bouron A
Phytother Res; 2024 Feb; 38(2):636-645. PubMed ID: 37963759
[TBL] [Abstract][Full Text] [Related]
5. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S
Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
[TBL] [Abstract][Full Text] [Related]
6. TRPC6 channel-mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of RAS/MEK/ERK, PI3K, and CAMKIV signaling.
Heiser JH; Schuwald AM; Sillani G; Ye L; Müller WE; Leuner K
J Neurochem; 2013 Nov; 127(3):303-13. PubMed ID: 23875811
[TBL] [Abstract][Full Text] [Related]
7. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels.
Leuner K; Kazanski V; Müller M; Essin K; Henke B; Gollasch M; Harteneck C; Müller WE
FASEB J; 2007 Dec; 21(14):4101-11. PubMed ID: 17666455
[TBL] [Abstract][Full Text] [Related]
8. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca(2+) -permeable TRPC6 channels.
Leuner K; Li W; Amaral MD; Rudolph S; Calfa G; Schuwald AM; Harteneck C; Inoue T; Pozzo-Miller L
Hippocampus; 2013 Jan; 23(1):40-52. PubMed ID: 22815087
[TBL] [Abstract][Full Text] [Related]
9. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H
Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
[TBL] [Abstract][Full Text] [Related]
11. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
Vacek J; Klejdus B; Kubán V
Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
[TBL] [Abstract][Full Text] [Related]
12. Role of hyperforin in the pharmacological activities of St. John's Wort.
Zanoli P
CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility.
Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA
J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886
[TBL] [Abstract][Full Text] [Related]
14. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
[TBL] [Abstract][Full Text] [Related]
15. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Wurglics M; Schubert-Zsilavecz M
Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
[TBL] [Abstract][Full Text] [Related]
16. Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore.
Leuner K; Heiser JH; Derksen S; Mladenov MI; Fehske CJ; Schubert R; Gollasch M; Schneider G; Harteneck C; Chatterjee SS; Müller WE
Mol Pharmacol; 2010 Mar; 77(3):368-77. PubMed ID: 20008516
[TBL] [Abstract][Full Text] [Related]
17. Current St John's wort research from mode of action to clinical efficacy.
Müller WE
Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
[TBL] [Abstract][Full Text] [Related]
18. The Biochemical and Genetic Basis for the Biosynthesis of Bioactive Compounds in
Rizzo P; Altschmied L; Ravindran BM; Rutten T; D'Auria JC
Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33081197
[No Abstract] [Full Text] [Related]
19. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
Muruganandam AV; Bhattacharya SK; Ghosal S
Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
[TBL] [Abstract][Full Text] [Related]
20. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.
Butterweck V; Nahrstedt A; Evans J; Hufeisen S; Rauser L; Savage J; Popadak B; Ernsberger P; Roth BL
Psychopharmacology (Berl); 2002 Jul; 162(2):193-202. PubMed ID: 12110997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
